European approval for Novo’s Esperoct in haemophilia A

pharmafile | June 21, 2019 | News story | Medical Communications, Sales and Marketing Esperoct, Novo Nordisk, haemophilia, pharma 

The European Commission has awarded approval to Novo Nordisk’s extended half-life factor VIII therapy Esperoct (turoctocog alfa pegol, N8-GP) for the treatment of haemophilia A in adolescent and adult patients, the drugmaker has revealed.

Specifically, the approval covers “the prophylaxis and on-demand treatment of bleeding as well as for surgical procedures”. The decision from the EC comes after a positive opinion from the Committee for Medicinal Products for Human Use in April, and was based on data derived from the largest pre-registration clinical programme ever undertaken in this disease area, demonstrating the therapy’s efficacy in 270 previously untreated severe haemophilia A patients over five years.

“We are excited about the approval of Esperoct® in the EU, and we consider it an important expansion of the treatment options for patients with haemophilia A,” said Mads Krogsgaard Thomsen, Executive Vice President and Chief Science Officer of Novo Nordisk. “We are confident that Esperoct® will provide people with haemophilia A a simple and less burdensome, predictable dosing regimen for prophylaxis as well as treatment of bleeding episodes, resulting in improved quality of life.”

Esperoct is expected to launch in Europe in the second half of the year.

Matt Fellows

Related Content

Novo Nordisk partners with UNICEF to prevent global childhood obesity

Novo Nordisk and UNICEF have announced an extension to their long-term partnership aiming to prevent …

Novo Nordisk launches Wegovy in the UK

Novo Nordisk has today announced that Wegovy (semaglutide injection) is now available in the UK …

Novo Nordisk acquires Embark Biotech and its lead metabolic programme

Novo Nordisk has officially acquired the biopharmaceutical company Embark Biotech, along with its lead asset …

Latest content